Skip to content

    Recently Viewed


      Home / Latest news / Innovation /
      The next stem cell frontier: diabetes
      Viacyte Blog

      The next stem cell frontier: diabetes

      Share Article
      share to

      When you think of stem cell treatments, you probably picture a patient with an immune disorder or cancer. But thanks to a new partnership between Johnson & Johnson’s Janssen Biotech, Inc. and biotech company ViaCyte, Inc., there’s a new wave of stem cell research being conducted that holds a lot of promise for people with Type 1 diabetes.

      According to the American Diabetes Association, approximately 1.25 million Americans have Type 1 diabetes. Although the exact cause of Type 1 diabetes isn’t known, in most cases, the body’s immune system mistakenly attacks healthy pancreatic cells. As a result, people lose the ability to make insulin—a hormone that allows the body to convert glucose from food into energy—causing sugar to build up in the bloodstream.

      Over time, people with Type 1 diabetes can develop serious complications, such as blindness, heart disease, nerve damage, and kidney failure. So patients have to closely monitor what they eat, test their blood sugar up to six or more times a day, and carefully balance their insulin levels using injections or insulin pumps.

      But ViaCyte’s work with VC-01™ could change all of that.

      The VC-01™ product uses two unique technologies. First, embryonic stem cells are turned into immature pancreas cells. These “starter cells” are then placed into a small ViaCyte Encaptra® mesh capsule that’s inserted just beneath the skin on a patient’s back, where they can grow and mature into insulin-producing cells.

      Since body fluids can flow through the mesh, the cells are able to help regulate glucose in the blood. And while more research still needs to be done, it’s possible that, once implanted, the capsule could remain effective for several years before it needs to be replaced.

      “It’s like [having] a whole new pancreas,” explains Diego Miralles, MD, head of Johnson & Johnson Innovation. “It will be able to completely control the blood glucose of a person without them needing to measure their blood or inject insulin, enabling them to lead a normal life.”

      The treatment is currently being tested on patients through clinical trials in the U.S. and Canada, with the hope that VC-01™ could be on the market in the next five to 10 years—and possibly even help people with Type 2 diabetes down the road.

      “It’s early, but we’ve seen encouraging signs,” Miralles says. “It’s difficult to make predictions, but we’re going in the right direction.”

      Stephanie Booth is a freelancer writer living in Portland, Oregon. Her stories have appeared in magazines like Real Simple, Glamour, Cosmopolitan and online at Salon, Psychology Today, and The Stir.

      More from Johnson & Johnson

      Latest news
      healthcare worker in protective medical gear

      Johnson & Johnson named to Fortune’s 2024 America’s Most Innovative Companies list

      The company’s drive to develop novel solutions for the world’s toughest healthcare challenges has earned it a spot on Fortune’s second annual list.
      Headshots of three Johnson and Johnson female scientists

      Meet 3 leaders who are breaking new ground for women in healthcare

      For International Women’s Day, celebrate the achievements of these amazing female scientists and researchers at Johnson & Johnson.
      Close-up of a woman with low vision receiving an eye exam exam with a doctor shining light into her left eye

      What is low vision?

      Low vision isn’t the same as blindness, but navigating daily life with it is still challenging. For Low Vision Awareness Month, learn the facts—plus, the promising treatment innovations that are in the works.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.